WO2020242719A3 - Inhibitors of rna-binding proteins, compositions thereof, and therapeutic uses thereof - Google Patents
Inhibitors of rna-binding proteins, compositions thereof, and therapeutic uses thereof Download PDFInfo
- Publication number
- WO2020242719A3 WO2020242719A3 PCT/US2020/031058 US2020031058W WO2020242719A3 WO 2020242719 A3 WO2020242719 A3 WO 2020242719A3 US 2020031058 W US2020031058 W US 2020031058W WO 2020242719 A3 WO2020242719 A3 WO 2020242719A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rna
- compositions
- inhibitors
- binding proteins
- therapeutic uses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
The present technology is directed to compounds that inhibit of the interaction of RNA-binding protiens with RNA, intermediaes thereof, compositions thereof, and methods of treatment utilizing such compounds, where the compounds are of Formula (I).
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/607,003 US20220213052A1 (en) | 2019-05-01 | 2020-05-01 | Inhibitors of rna-binding proteins, compositions thereof, and therapeutic uses therof |
EP20813936.0A EP3963085A4 (en) | 2019-05-01 | 2020-05-01 | Inhibitors of rna-binding proteins, compositions thereof, and therapeutic uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962841600P | 2019-05-01 | 2019-05-01 | |
US62/841,600 | 2019-05-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020242719A2 WO2020242719A2 (en) | 2020-12-03 |
WO2020242719A3 true WO2020242719A3 (en) | 2021-02-25 |
Family
ID=73553089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/031058 WO2020242719A2 (en) | 2019-05-01 | 2020-05-01 | Inhibitors of rna-binding proteins, compositions thereof, and therapeutic uses thereof |
Country Status (3)
Country | Link |
---|---|
US (1) | US20220213052A1 (en) |
EP (1) | EP3963085A4 (en) |
WO (1) | WO2020242719A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230131501A1 (en) * | 2020-03-30 | 2023-04-27 | University Of Kansas | THERAPEUTIC USES OF INHIBITORS OF THE RNA-BINDING PROTEIN HuR |
CN117448332A (en) * | 2023-08-07 | 2024-01-26 | 大连理工大学 | Sequence optimization method for enhancing mRNA protein expression by using RNA binding protein |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6153642A (en) * | 1996-11-11 | 2000-11-28 | Pharmacia & Upjohn S.P.A. | Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843937A (en) * | 1996-05-23 | 1998-12-01 | Panorama Research, Inc. | DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents |
US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
TWI412367B (en) * | 2006-12-28 | 2013-10-21 | Medarex Llc | Chemical linkers and cleavable substrates and conjugates thereof |
HUE035798T2 (en) * | 2008-11-03 | 2018-05-28 | Syntarga Bv | Cc-1065 analogs and their conjugates |
WO2011050325A1 (en) * | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
-
2020
- 2020-05-01 WO PCT/US2020/031058 patent/WO2020242719A2/en unknown
- 2020-05-01 US US17/607,003 patent/US20220213052A1/en active Pending
- 2020-05-01 EP EP20813936.0A patent/EP3963085A4/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6153642A (en) * | 1996-11-11 | 2000-11-28 | Pharmacia & Upjohn S.P.A. | Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents |
Non-Patent Citations (3)
Title |
---|
ALLAN ET AL.: "N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 19, 2009, pages 1218 - 1223, XP025937250, DOI: 10.1016/j.bmcl.2008.12.075 * |
DATABASE PubChem COMPOUND 26 April 2019 (2019-04-26), "5-(1H-Indole-7-carbonylamino)-1-benzofuran-2-carboxylic acid | C18H12N2O4", XP055795746, Database accession no. CID 137990205 * |
DATABASE PubChem Compound NCBI; 23 July 2010 (2010-07-23), Database accession no. CID 46424910 * |
Also Published As
Publication number | Publication date |
---|---|
EP3963085A4 (en) | 2022-09-14 |
WO2020242719A2 (en) | 2020-12-03 |
US20220213052A1 (en) | 2022-07-07 |
EP3963085A2 (en) | 2022-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022015812A (en) | Inhibitors of cysteine proteases and methods of use thereof. | |
MX2022005839A (en) | Compounds useful as inhibitors of helios protein. | |
EA202092001A1 (en) | COMPOUNDS FOR TREATMENT OF GENTINGTON'S DISEASE | |
MX2020001598A (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5). | |
EA202092896A1 (en) | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF GENTINGTON'S DISEASE | |
MX2020013817A (en) | Substituted naphthyridinone compounds useful as t cell activators. | |
EA201991399A1 (en) | AMINOTRIAZOLOPYRIDINE COMPOUNDS AND THEIR APPLICATION IN TREATMENT OF CANCER | |
MX2021001186A (en) | Purinones as ubiquitin-specific protease 1 inhibitors. | |
EA202092899A1 (en) | HETEROARYL COMPOUNDS FOR THE TREATMENT OF GENTINGTON'S DISEASE | |
MX2020013416A (en) | Tertiary amine substituted coumarin compounds and their uses as fluorescent labels. | |
MX2021013299A (en) | Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response. | |
MX2020002399A (en) | Inhibitors of wdr5 protein-protein binding. | |
MX2020007944A (en) | Lipid-like nanocomplexes and uses thereof. | |
MX2020013853A (en) | Novel compounds. | |
MX2020009234A (en) | Heteroaryl compounds as type ii irak inhibitors and uses hereof. | |
TW200745004A (en) | Novel compounds, their preparation and use | |
DK2358717T3 (en) | AMINOTETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS TREATMENT OR PREVENTION OF DIABETES | |
MX2022007372A (en) | Substituted heteroaryl compounds useful as t cell activators. | |
AU2020317609A8 (en) | Novel heteroaryl-triazole compounds as pesticides | |
MX2023003264A (en) | Cdk inhibitors and their use as pharmaceuticals. | |
MX2022011601A (en) | Substituted oxoisoindoline compounds for the treatment of cancer. | |
WO2019152419A8 (en) | Prc2 inhibitors | |
MX2021006619A (en) | Tyrosine kinase inhibitors, compositions and methods there of. | |
EA200501399A1 (en) | DERIVATIVES OF BENZOPIRANE THAT CAN BE USED IN THE TREATMENT OF INFLAMMATORY DISEASES | |
WO2020242719A3 (en) | Inhibitors of rna-binding proteins, compositions thereof, and therapeutic uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020813936 Country of ref document: EP Effective date: 20211201 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20813936 Country of ref document: EP Kind code of ref document: A2 |